NCT01580397View on ClinicalTrials.gov

Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 16, 2012

Primary Completion Date

May 13, 2013

Study Completion Date

July 2, 2013

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

INNO-206

INNO-206 at a total dose of 350 mg/m2 (260 mg/m2 doxorubicin equivalent) will be administered as a 30 minute IV infusion every 21 days.

Trial Locations (6)

53266

Medical College of Wisconsin - Division of Neoplastic Diseases and Related Disorders, Milwaukee

85258

Scottsdale Healthcare, Scottsdale

90048

Samuel Oschin Comprehensive Cancer Institute, Los Angeles

90403

Sarcoma Oncology Center, Santa Monica

55407-3799

Virginia Piper Cancer Institute, Minneapolis

08901

Cancer Institute of New Jersey, New Brunswick

Sponsors

Lead Sponsor

ImmunityBio, Inc.
All Listed Sponsors
lead

ImmunityBio, Inc.

INDUSTRY

NCT01580397 - Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter